Overview

A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy

Status:
Recruiting

Trial end date:
2022-02-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 52.

Phase:

Phase 4

Details

Lead Sponsor:

Celltrion Pharm, Inc.
Takeda

Treatments:

Alogliptin
Dapagliflozin
Glimepiride
Metformin
Pioglitazone